Ocugen said it will take its gene therapy for a form of vision loss into a Phase 3 trial, after reporting mixed results on Tuesday

Given his former role as US national coordinator for health IT, you might expect that Farzad Mostashari would be an AI enthusiast. But his experience

The FDA warned California-based ImmunityBio for a TV advertisement and podcast that gave the “misleading impression” that Anktiva, the company’s treatment for a type of

Despite hitting just one of two efficacy endpoints in a pivotal trial, Karyopharm thinks it still has a path to approval for Xpovio in myelofibrosis.

The UK’s medicines regulator is backing developers using non‑animal methods, offering early data reviews to help phase out animal testing while keeping medicines safe and